Celecoxib (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Celecoxib" in Italian language version.

refsWebsite

Global rank Italian rank

37nih.gov

4^th place

9^th place

17doi.org

2^nd place

7^th place

13oadoi.org

799^th place

22^nd place

6archive.org

6^th place

8^th place

archive.org

CO. Bingham, AI. Sebba; BR. Rubin; GE. Ruoff; J. Kremer; S. Bird; SS. Smugar; BJ. Fitzgerald; K. O'Brien; AM. Tershakovec, Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies., in Rheumatology (Oxford), vol. 46, n. 3, Mar 2007, pp. 496-507, DOI:10.1093/rheumatology/kel296, PMID 16936327.
TJ. Schnitzer, AL. Weaver; AB. Polis; RA. Petruschke; GP. Geba, Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies., in J Rheumatol, vol. 32, n. 6, Jun 2005, pp. 1093-105, PMID 15940774.
I. Foeldvari, IS. Szer; LS. Zemel; DJ. Lovell; EH. Giannini; JL. Robbins; CR. West; G. Steidle; S. Krishnaswami; BJ. Bloom, A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis., in J Rheumatol, vol. 36, n. 1, Jan 2009, pp. 174-82, DOI:10.3899/jrheum.080073, PMID 19012356.
A. Barkhuizen, S. Steinfeld; J. Robbins; C. West; J. Coombs; S. Zwillich, Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis., in J Rheumatol, vol. 33, n. 9, Sep 2006, pp. 1805-12, PMID 16960941.
G. Singh, JG. Fort; JL. Goldstein; RA. Levy; PS. Hanrahan; AE. Bello; L. Andrade-Ortega; C. Wallemark; NM. Agrawal; GM. Eisen; WF. Stenson, Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study., in Am J Med, vol. 119, n. 3, Mar 2006, pp. 255-66, DOI:10.1016/j.amjmed.2005.09.054, PMID 16490472.
GP. Joshi, R. Gertler; R. Fricker, Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs., in Anesth Analg, vol. 105, n. 6, Dec 2007, pp. 1793-804, table of contents, DOI:10.1213/01.ane.0000286229.05723.50, PMID 18042885.

doi.org

dx.doi.org

TD. Penning, JJ. Talley; SR. Bertenshaw; JS. Carter; PW. Collins; S. Docter; MJ. Graneto; LF. Lee; JW. Malecha; JM. Miyashiro; RS. Rogers, Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib)., in J Med Chem, vol. 40, n. 9, Apr 1997, pp. 1347-65, DOI:10.1021/jm960803q, PMID 9135032.
CO. Bingham, AI. Sebba; BR. Rubin; GE. Ruoff; J. Kremer; S. Bird; SS. Smugar; BJ. Fitzgerald; K. O'Brien; AM. Tershakovec, Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies., in Rheumatology (Oxford), vol. 46, n. 3, Mar 2007, pp. 496-507, DOI:10.1093/rheumatology/kel296, PMID 16936327.
WP. Battisti, NP. Katz; AL. Weaver; AK. Matsumoto; AJ. Kivitz; AB. Polis; GP. Geba, Pain management in osteoarthritis: a focus on onset of efficacy--a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials., in J Pain, vol. 5, n. 9, Nov 2004, pp. 511-20, DOI:10.1016/j.jpain.2004.09.004, PMID 15556830.
FK. Chan, A. Lanas; J. Scheiman; MF. Berger; H. Nguyen; JL. Goldstein, Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial., in Lancet, vol. 376, n. 9736, Jul 2010, pp. 173-9, DOI:10.1016/S0140-6736(10)60673-3, PMID 20638563.
I. Foeldvari, IS. Szer; LS. Zemel; DJ. Lovell; EH. Giannini; JL. Robbins; CR. West; G. Steidle; S. Krishnaswami; BJ. Bloom, A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis., in J Rheumatol, vol. 36, n. 1, Jan 2009, pp. 174-82, DOI:10.3899/jrheum.080073, PMID 19012356.
J. Sieper, T. Klopsch; M. Richter; A. Kapelle; M. Rudwaleit; S. Schwank; E. Regourd; M. May, Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study., in Ann Rheum Dis, vol. 67, n. 3, Mar 2008, pp. 323-9, DOI:10.1136/ard.2007.075309, PMID 17616556.
PL. McCormack, Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis., in Drugs, vol. 71, n. 18, Dec 2011, pp. 2457-89, DOI:10.2165/11208240-000000000-00000, PMID 22141388.
G. Singh, JG. Fort; JL. Goldstein; RA. Levy; PS. Hanrahan; AE. Bello; L. Andrade-Ortega; C. Wallemark; NM. Agrawal; GM. Eisen; WF. Stenson, Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study., in Am J Med, vol. 119, n. 3, Mar 2006, pp. 255-66, DOI:10.1016/j.amjmed.2005.09.054, PMID 16490472.
MM. Bertagnolli, CJ. Eagle; AG. Zauber; M. Redston; SD. Solomon; K. Kim; J. Tang; RB. Rosenstein; J. Wittes; D. Corle; TM. Hess, Celecoxib for the prevention of sporadic colorectal adenomas., in N Engl J Med, vol. 355, n. 9, Aug 2006, pp. 873-84, DOI:10.1056/NEJMoa061355, PMID 16943400.
SD. Solomon, JJ. McMurray; MA. Pfeffer; J. Wittes; R. Fowler; P. Finn; WF. Anderson; A. Zauber; E. Hawk; M. Bertagnolli, Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention., in N Engl J Med, vol. 352, n. 11, Mar 2005, pp. 1071-80, DOI:10.1056/NEJMoa050405, PMID 15713944.
N. Arber, CJ. Eagle; J. Spicak; I. Rácz; P. Dite; J. Hajer; M. Zavoral; MJ. Lechuga; P. Gerletti; J. Tang; RB. Rosenstein, Celecoxib for the prevention of colorectal adenomatous polyps., in N Engl J Med, vol. 355, n. 9, Aug 2006, pp. 885-95, DOI:10.1056/NEJMoa061652, PMID 16943401.
SD. Solomon, MA. Pfeffer; JJ. McMurray; R. Fowler; P. Finn; B. Levin; C. Eagle; E. Hawk; M. Lechuga; AG. Zauber; MM. Bertagnolli, Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas., in Circulation, vol. 114, n. 10, Sep 2006, pp. 1028-35, DOI:10.1161/CIRCULATIONAHA.106.636746, PMID 16943394.
GA. FitzGerald, COX-2 and beyond: Approaches to prostaglandin inhibition in human disease., in Nat Rev Drug Discov, vol. 2, n. 11, Nov 2003, pp. 879-90, DOI:10.1038/nrd1225, PMID 14668809.
WA. Ray, TM. MacDonald; DH. Solomon; DJ. Graham; J. Avorn, COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease., in Pharmacoepidemiol Drug Saf, vol. 12, n. 1, Gen-Feb 2003, pp. 67-70, DOI:10.1002/pds.798, PMID 12616850.
GA. Fitzgerald, Coxibs and cardiovascular disease., in N Engl J Med, vol. 351, n. 17, Oct 2004, pp. 1709-11, DOI:10.1056/NEJMp048288, PMID 15470192.
C. Bombardier, L. Laine; A. Reicin; D. Shapiro; R. Burgos-Vargas; B. Davis; R. Day; MB. Ferraz; CJ. Hawkey; MC. Hochberg; TK. Kvien, Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group., in N Engl J Med, vol. 343, n. 21, Nov 2000, pp. 1520-8, 2 p following 1528, DOI:10.1056/NEJM200011233432103, PMID 11087881.
GP. Joshi, R. Gertler; R. Fricker, Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs., in Anesth Analg, vol. 105, n. 6, Dec 2007, pp. 1793-804, table of contents, DOI:10.1213/01.ane.0000286229.05723.50, PMID 18042885.

nih.gov

ncbi.nlm.nih.gov

TD. Penning, JJ. Talley; SR. Bertenshaw; JS. Carter; PW. Collins; S. Docter; MJ. Graneto; LF. Lee; JW. Malecha; JM. Miyashiro; RS. Rogers, Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib)., in J Med Chem, vol. 40, n. 9, Apr 1997, pp. 1347-65, DOI:10.1021/jm960803q, PMID 9135032.
PE. Lipsky, Role of cyclooxygenase-1 and -2 in health and disease., in Am J Orthop (Belle Mead NJ), vol. 28, 3 Suppl, Mar 1999, pp. 8-12, PMID 10193997.
B. Hinz, K. Brune, [Specific COX-2 inhibitors: prospects of therapy with new analgesic and anti-inflammatory substances]., in Wien Klin Wochenschr, vol. 111, n. 3, Feb 1999, pp. 103-12, PMID 10093892.
J. Fort, Celecoxib, a COX-2--specific inhibitor: the clinical data., in Am J Orthop (Belle Mead NJ), vol. 28, 3 Suppl, Mar 1999, pp. 13-8, PMID 10193998.
E. Tindall, Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results., in J Am Osteopath Assoc, vol. 99, 11 Suppl, Nov 1999, pp. S13-7, PMID 10643176.
SS. Brenner, C. Herrlinger; K. Dilger; TE. Mürdter; U. Hofmann; C. Marx; U. Klotz, Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib., in Clin Pharmacokinet, vol. 42, n. 3, 2003, pp. 283-92, PMID 12603175.
NM. Davies, AJ. McLachlan; RO. Day; KM. Williams, Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor., in Clin Pharmacokinet, vol. 38, n. 3, Mar 2000, pp. 225-42, PMID 10749518.
CO. Bingham, AI. Sebba; BR. Rubin; GE. Ruoff; J. Kremer; S. Bird; SS. Smugar; BJ. Fitzgerald; K. O'Brien; AM. Tershakovec, Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies., in Rheumatology (Oxford), vol. 46, n. 3, Mar 2007, pp. 496-507, DOI:10.1093/rheumatology/kel296, PMID 16936327.
TJ. Schnitzer, AL. Weaver; AB. Polis; RA. Petruschke; GP. Geba, Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies., in J Rheumatol, vol. 32, n. 6, Jun 2005, pp. 1093-105, PMID 15940774.
WP. Battisti, NP. Katz; AL. Weaver; AK. Matsumoto; AJ. Kivitz; AB. Polis; GP. Geba, Pain management in osteoarthritis: a focus on onset of efficacy--a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials., in J Pain, vol. 5, n. 9, Nov 2004, pp. 511-20, DOI:10.1016/j.jpain.2004.09.004, PMID 15556830.
FK. Chan, A. Lanas; J. Scheiman; MF. Berger; H. Nguyen; JL. Goldstein, Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial., in Lancet, vol. 376, n. 9736, Jul 2010, pp. 173-9, DOI:10.1016/S0140-6736(10)60673-3, PMID 20638563.
YF. Chen, P. Jobanputra; P. Barton; S. Bryan; A. Fry-Smith; G. Harris; RS. Taylor, Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation., in Health Technol Assess, vol. 12, n. 11, Apr 2008, pp. 1-278, iii, PMID 18405470.
SZ. Zhao, JI. Fiechtner; EA. Tindall; SD. Dedhiya; WW. Zhao; JT. Osterhaus; SS. Yu, Evaluation of health-related quality of life of rheumatoid arthritis patients treated with celecoxib., in Arthritis Care Res, vol. 13, n. 2, Apr 2000, pp. 112-21, PMID 14635284.
I. Foeldvari, IS. Szer; LS. Zemel; DJ. Lovell; EH. Giannini; JL. Robbins; CR. West; G. Steidle; S. Krishnaswami; BJ. Bloom, A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis., in J Rheumatol, vol. 36, n. 1, Jan 2009, pp. 174-82, DOI:10.3899/jrheum.080073, PMID 19012356.
A. Barkhuizen, S. Steinfeld; J. Robbins; C. West; J. Coombs; S. Zwillich, Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis., in J Rheumatol, vol. 33, n. 9, Sep 2006, pp. 1805-12, PMID 16960941.
J. Sieper, T. Klopsch; M. Richter; A. Kapelle; M. Rudwaleit; S. Schwank; E. Regourd; M. May, Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study., in Ann Rheum Dis, vol. 67, n. 3, Mar 2008, pp. 323-9, DOI:10.1136/ard.2007.075309, PMID 17616556.
PL. McCormack, Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis., in Drugs, vol. 71, n. 18, Dec 2011, pp. 2457-89, DOI:10.2165/11208240-000000000-00000, PMID 22141388.
JE. Frampton, GM. Keating, Celecoxib: a review of its use in the management of arthritis and acute pain., in Drugs, vol. 67, n. 16, 2007, pp. 2433-72, PMID 17983259.
G. Singh, JG. Fort; JL. Goldstein; RA. Levy; PS. Hanrahan; AE. Bello; L. Andrade-Ortega; C. Wallemark; NM. Agrawal; GM. Eisen; WF. Stenson, Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study., in Am J Med, vol. 119, n. 3, Mar 2006, pp. 255-66, DOI:10.1016/j.amjmed.2005.09.054, PMID 16490472.
MM. Bertagnolli, CJ. Eagle; AG. Zauber; M. Redston; SD. Solomon; K. Kim; J. Tang; RB. Rosenstein; J. Wittes; D. Corle; TM. Hess, Celecoxib for the prevention of sporadic colorectal adenomas., in N Engl J Med, vol. 355, n. 9, Aug 2006, pp. 873-84, DOI:10.1056/NEJMoa061355, PMID 16943400.
SD. Solomon, JJ. McMurray; MA. Pfeffer; J. Wittes; R. Fowler; P. Finn; WF. Anderson; A. Zauber; E. Hawk; M. Bertagnolli, Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention., in N Engl J Med, vol. 352, n. 11, Mar 2005, pp. 1071-80, DOI:10.1056/NEJMoa050405, PMID 15713944.
N. Arber, CJ. Eagle; J. Spicak; I. Rácz; P. Dite; J. Hajer; M. Zavoral; MJ. Lechuga; P. Gerletti; J. Tang; RB. Rosenstein, Celecoxib for the prevention of colorectal adenomatous polyps., in N Engl J Med, vol. 355, n. 9, Aug 2006, pp. 885-95, DOI:10.1056/NEJMoa061652, PMID 16943401.
SD. Solomon, MA. Pfeffer; JJ. McMurray; R. Fowler; P. Finn; B. Levin; C. Eagle; E. Hawk; M. Lechuga; AG. Zauber; MM. Bertagnolli, Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas., in Circulation, vol. 114, n. 10, Sep 2006, pp. 1028-35, DOI:10.1161/CIRCULATIONAHA.106.636746, PMID 16943394.
JB. Hrachovec, M. Mora, Reporting of 6-month vs 12-month data in a clinical trial of celecoxib., in JAMA, vol. 286, n. 19, Nov 2001, pp. 2398; author reply 2399-400, PMID 11712924.
JM. Wright, TL. Perry; KL. Bassett; GK. Chambers, Reporting of 6-month vs 12-month data in a clinical trial of celecoxib., in JAMA, vol. 286, n. 19, Nov 2001, pp. 2398-400, PMID 11712925.
P. Jüni, AW. Rutjes; PA. Dieppe, Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?, in BMJ, vol. 324, n. 7349, Jun 2002, pp. 1287-8, PMID 12039807.
S. Gottlieb, Researchers deny any attempt to mislead the public over JAMA article on arthritis drug., in BMJ, vol. 323, n. 7308, Aug 2001, p. 301, PMID 11498480.
P. Juni, R. Sterchi; P. Dieppe, Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Problems compromise review's validity., in BMJ, vol. 326, n. 7384, Feb 2003, pp. 334; author reply 334, PMID 12574052.
A. Whelton, JG. Fort; JA. Puma; D. Normandin; AE. Bello; KM. Verburg, Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients., in Am J Ther, vol. 8, n. 2, pp. 85-95, PMID 11304662.
A. Whelton, COX-2-specific inhibitors and the kidney: effect on hypertension and oedema., in J Hypertens Suppl, vol. 20, n. 6, Sep 2002, pp. S31-5, PMID 12683425.
GA. FitzGerald, COX-2 and beyond: Approaches to prostaglandin inhibition in human disease., in Nat Rev Drug Discov, vol. 2, n. 11, Nov 2003, pp. 879-90, DOI:10.1038/nrd1225, PMID 14668809.
WA. Ray, TM. MacDonald; DH. Solomon; DJ. Graham; J. Avorn, COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease., in Pharmacoepidemiol Drug Saf, vol. 12, n. 1, Gen-Feb 2003, pp. 67-70, DOI:10.1002/pds.798, PMID 12616850.
GA. Fitzgerald, Coxibs and cardiovascular disease., in N Engl J Med, vol. 351, n. 17, Oct 2004, pp. 1709-11, DOI:10.1056/NEJMp048288, PMID 15470192.
C. Bombardier, L. Laine; A. Reicin; D. Shapiro; R. Burgos-Vargas; B. Davis; R. Day; MB. Ferraz; CJ. Hawkey; MC. Hochberg; TK. Kvien, Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group., in N Engl J Med, vol. 343, n. 21, Nov 2000, pp. 1520-8, 2 p following 1528, DOI:10.1056/NEJM200011233432103, PMID 11087881.
FE. Silverstein, G. Faich; JL. Goldstein; LS. Simon; T. Pincus; A. Whelton; R. Makuch; G. Eisen; NM. Agrawal; WF. Stenson; AM. Burr, Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study., in JAMA, vol. 284, n. 10, Sep 2000, pp. 1247-55, PMID 10979111.
D. Mukherjee, SE. Nissen; EJ. Topol, Risk of cardiovascular events associated with selective COX-2 inhibitors., in JAMA, vol. 286, n. 8, pp. 954-9, PMID 11509060.
GP. Joshi, R. Gertler; R. Fricker, Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs., in Anesth Analg, vol. 105, n. 6, Dec 2007, pp. 1793-804, table of contents, DOI:10.1213/01.ane.0000286229.05723.50, PMID 18042885.

oadoi.org

TD. Penning, JJ. Talley; SR. Bertenshaw; JS. Carter; PW. Collins; S. Docter; MJ. Graneto; LF. Lee; JW. Malecha; JM. Miyashiro; RS. Rogers, Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib)., in J Med Chem, vol. 40, n. 9, Apr 1997, pp. 1347-65, DOI:10.1021/jm960803q, PMID 9135032.
WP. Battisti, NP. Katz; AL. Weaver; AK. Matsumoto; AJ. Kivitz; AB. Polis; GP. Geba, Pain management in osteoarthritis: a focus on onset of efficacy--a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials., in J Pain, vol. 5, n. 9, Nov 2004, pp. 511-20, DOI:10.1016/j.jpain.2004.09.004, PMID 15556830.
FK. Chan, A. Lanas; J. Scheiman; MF. Berger; H. Nguyen; JL. Goldstein, Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial., in Lancet, vol. 376, n. 9736, Jul 2010, pp. 173-9, DOI:10.1016/S0140-6736(10)60673-3, PMID 20638563.
J. Sieper, T. Klopsch; M. Richter; A. Kapelle; M. Rudwaleit; S. Schwank; E. Regourd; M. May, Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study., in Ann Rheum Dis, vol. 67, n. 3, Mar 2008, pp. 323-9, DOI:10.1136/ard.2007.075309, PMID 17616556.
PL. McCormack, Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis., in Drugs, vol. 71, n. 18, Dec 2011, pp. 2457-89, DOI:10.2165/11208240-000000000-00000, PMID 22141388.
MM. Bertagnolli, CJ. Eagle; AG. Zauber; M. Redston; SD. Solomon; K. Kim; J. Tang; RB. Rosenstein; J. Wittes; D. Corle; TM. Hess, Celecoxib for the prevention of sporadic colorectal adenomas., in N Engl J Med, vol. 355, n. 9, Aug 2006, pp. 873-84, DOI:10.1056/NEJMoa061355, PMID 16943400.
SD. Solomon, JJ. McMurray; MA. Pfeffer; J. Wittes; R. Fowler; P. Finn; WF. Anderson; A. Zauber; E. Hawk; M. Bertagnolli, Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention., in N Engl J Med, vol. 352, n. 11, Mar 2005, pp. 1071-80, DOI:10.1056/NEJMoa050405, PMID 15713944.
N. Arber, CJ. Eagle; J. Spicak; I. Rácz; P. Dite; J. Hajer; M. Zavoral; MJ. Lechuga; P. Gerletti; J. Tang; RB. Rosenstein, Celecoxib for the prevention of colorectal adenomatous polyps., in N Engl J Med, vol. 355, n. 9, Aug 2006, pp. 885-95, DOI:10.1056/NEJMoa061652, PMID 16943401.
SD. Solomon, MA. Pfeffer; JJ. McMurray; R. Fowler; P. Finn; B. Levin; C. Eagle; E. Hawk; M. Lechuga; AG. Zauber; MM. Bertagnolli, Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas., in Circulation, vol. 114, n. 10, Sep 2006, pp. 1028-35, DOI:10.1161/CIRCULATIONAHA.106.636746, PMID 16943394.
GA. FitzGerald, COX-2 and beyond: Approaches to prostaglandin inhibition in human disease., in Nat Rev Drug Discov, vol. 2, n. 11, Nov 2003, pp. 879-90, DOI:10.1038/nrd1225, PMID 14668809.
WA. Ray, TM. MacDonald; DH. Solomon; DJ. Graham; J. Avorn, COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease., in Pharmacoepidemiol Drug Saf, vol. 12, n. 1, Gen-Feb 2003, pp. 67-70, DOI:10.1002/pds.798, PMID 12616850.
GA. Fitzgerald, Coxibs and cardiovascular disease., in N Engl J Med, vol. 351, n. 17, Oct 2004, pp. 1709-11, DOI:10.1056/NEJMp048288, PMID 15470192.
C. Bombardier, L. Laine; A. Reicin; D. Shapiro; R. Burgos-Vargas; B. Davis; R. Day; MB. Ferraz; CJ. Hawkey; MC. Hochberg; TK. Kvien, Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group., in N Engl J Med, vol. 343, n. 21, Nov 2000, pp. 1520-8, 2 p following 1528, DOI:10.1056/NEJM200011233432103, PMID 11087881.